All In Biotech

NDA 205920 · Armstrong Pharms

Primatene Mist

Epinephrine · Inhalation · alpha-Adrenergic Agonist; beta-Adrenergic Agonist; Catecholamine

Last checked: Nov 20, 2026Latest source record: Nov 7, 2018 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2018

Nov 7, 2018

Approved uses

1

Original approval plus efficacy supplements

Registered trials

2,347

454 Phase 3, 232 recruiting

FAERS reports

496

273 serious, 21 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jun 16, 2026.

Uses for temporary relief of mild symptoms of intermittent asthma ■ wheezing ■ tightness of chest ■ shortness of breath

Therapeutic areas: Kidney and urology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Nov 7, 2018 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • PRIMATENE MIST · EPINEPHRINE 0.125MG/INH · AEROSOL, METERED, INHALATION · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Epinephrine" as an intervention, any sponsor and status, largest first.

All 2,347 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective94
  • dyspnoea60
  • asthma33
  • chest pain31
  • throat irritation29
  • burning sensation28
  • cough25
  • dizziness23
  • heart rate increased19
  • headache17
  • tremor16
  • condition aggravated15

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
200417
200511
200642
200717
2008112
200914
201013
201118
201216
20131
20143
20153
20163
20182
201920
202034
202137
202231
202331
202415
202529
202627

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 4,529 on PubMed

Sponsor: Armstrong Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.